It takes the average reader 11 hours and 31 minutes to read Chapter 35: The Importance of Geographic Differences in Pediatric Clinical Trials by Andrew E. Mulberg
Assuming a reading speed of 250 words per minute. Learn more
The first comprehensive treatmentof this vital topicFor decades, the specific needs of infants, children, and adolescents have been largely ignored in the drug development process, and healthcare providers have most often had to make do with pediatric dosing of drugs that were developed and intended for adults. Now, an awareness of the differences between the pediatric patient and the adult patient have begun to be realized and addressed by the pharmaceutical and wider healthcare industries, as well as the governmental and regulatory bodies that sanction the development and testing of drugs for children.This is the first book to provide a comprehensive treatment of pediatric drug development. Written by a team of experts, it provides industry, academia, and governmental agencies with an understanding of how to properly develop drugs for children without compromising business objectives. The authors address the scientific differences between the pediatric and adult subject in the development of pharmaceutical products. They discuss and consider: ethics--from product concept to production; specific medical needs of children; business rationale for the proper development of drugs for children; and the technical feasibility of studies and processes that are necessary for a proper pediatric drug development program.The book clearly explains the challenges and opportunities facing the entire healthcare community as it strives to improve the health of children worldwide. It demonstrates how these approaches will benefit all stakeholders and, ultimately, provide better and safer drugs for the pediatric population at large.This timely new work is essential reading for academic researchers, pharmaceutical managers and executives, healthcare clinicians, policymakers, regulators, and lobbyists with an interest in pediatric drug development. It also serves as an important textbook for students in pharmacy, science, and medicine courses.
Chapter 35: The Importance of Geographic Differences in Pediatric Clinical Trials by Andrew E. Mulberg is 683 pages long, and a total of 172,799 words.
This makes it 231% the length of the average book. It also has 211% more words than the average book.
The average oral reading speed is 183 words per minute. This means it takes 15 hours and 44 minutes to read Chapter 35: The Importance of Geographic Differences in Pediatric Clinical Trials aloud.
Chapter 35: The Importance of Geographic Differences in Pediatric Clinical Trials is suitable for students ages 12 and up.
Note that there may be other factors that effect this rating besides length that are not factored in on this page. This may include things like complex language or sensitive topics not suitable for students of certain ages.
When deciding what to show young students always use your best judgement and consult a professional.
Chapter 35: The Importance of Geographic Differences in Pediatric Clinical Trials by Andrew E. Mulberg is sold by several retailers and bookshops. However, Read Time works with Amazon to provide an easier way to purchase books.
To buy Chapter 35: The Importance of Geographic Differences in Pediatric Clinical Trials by Andrew E. Mulberg on Amazon click the button below.
Buy Chapter 35: The Importance of Geographic Differences in Pediatric Clinical Trials on Amazon